PRPO News & Events

Precipio has announced the publication in the Journal of Clinical Pathology of a study conducted in collaboration with the Memorial Sloan-Kettering Cancer Center, demonstrating Precipio's new Bloodhound BCR::ABL1 assay for Chronic Myeloid Leukemia, CML. Ilan Danieli, CEO of Precipio, expanded on these findings. "Our Bloodhound BCR::ABL1 assay is the first and only assay that simultaneously detects and quantifies all four clinically important variants of BCR::ABL1 (isoforms). Precipio is first to apply the International Scale to create a novel assay quantifying all four variants, setting a new standard for monitoring patients with CML. Now, for the first time, clinicians can comprehensively monitor disease progression."

"Becoming an EBITDA and cash-flow positive business has a very important impact on how we manage the business. It allows us to now invest in growth projects that consider a longer-term perspective for the Company, rather than a constant focus on short-term cash burn considerations." said Ilan Danieli, CEO. "2025 was a great year for us, one where the business performed well, and shareholders saw their value triple. We are confident in our ability to continue to create this value."

Precipio has made strides in cleaning up its balance sheet with two accomplishments: A $1.1M advance from Change Healthcare has been repaid. CHC experienced a cybersecurity incident in 2024 and advanced Precipio and others funds to cover collections shortfalls. In early January 2026, the Company completed its repayment of that advance. Precipio maintains a small loan with the Connecticut Department of Economic and Community Development in the approximate principal amount of $80,000. Other than this minor loan, Precipio has a debt-free balance sheet. As part of a 2023 financing, the Company issued warrants to participating investors. In Q3 and Q4 of 2025, a portion of those warrants were exercised in normal manner, and the remainder were exercised cashless to reduce dilution to shareholders. At this point, all financial warrants have been exercised, and Precipio has no further financial warrants outstanding. Remaining are 10,000 warrants given to a vendor for services provided in 2022 in lieu of cash payment, at a strike price of $60, and expiring February 2027.

Precipio reports that the Company recently identified a single, limited scope unauthorized access to a specific data folder stored within its secure cloud file environment. The company said, "The incident was limited to its file storage server and did not impact any of Precipio's operations, diagnostics processes, or customer services, and the company continued to provide its services unhindered. There was no impact to patient care; nor impact to the company's operations or finances. Upon detecting the activity, the Company immediately initiated its incident response procedures and engaged an external cybersecurity law firm and forensic specialists to assist in the investigation and to help ensure the security of its systems. Precipio also took prompt steps to secure the environment, reset passwords company wide, and enhance monitoring and at this time, we are not seeing evidence of continued unauthorized access. While the investigation remains ongoing, current findings indicate that an unauthorized third party accessed and downloaded certain historical files within the customer service folder. Initial investigation shows that the majority of these files contained previously used operational procedures, temperature logs, vendor invoices and similar historical information which poses no risk or damage to the company. No patient Social Security numbers, addresses, or other patient financial information was included. Additionally, no company proprietary or financial data was included in the folders that were breached. We are pursuing a thorough investigation with top-tier cybersecurity partners, and although the review is ongoing, our current assessment strongly suggests that the incident was limited in scope and that our systems are stable. Precipio maintains a comprehensive cybersecurity insurance policy and expects that costs associated with the investigation, forensic analysis, and related response efforts will be covered in accordance with policy terms. Based on the information available at this time the company does not anticipate any material impact to its operations, customers, patient care, or to its shareholders as a result of this incident."